We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The company is currently conducting a pivotal investigational device exemption (IDE) trial evaluating the implant’s superiority over current surgical standard of care, microfracture and debridement; 251 participants have been enrolled. Read More
An early version of Thrive’s liquid biopsy test detected 10 different types of cancer, including seven with no recommended screening guidelines, Exact Sciences said. Read More
DIOSynVax is developing its COVID-19 vaccine using computer modeling to identify the virus’ genetic code in the hopes of producing a vaccine that is specific to developing antibodies against SARS-CoV-2. Read More